Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma

Vaccination With Idiotype-KLH Loaded Dendritic Cells. A Phase I Study for Patients With Multiple Myeloma

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00988312

Enrollment

Registered

2009-10-02

Start date

2002-03-31

Completion date

2004-03-31

Last updated

2009-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma, Plasmocytoma

Keywords

dendritic cells (DC), idiotype (Id), immunotherapy

Brief summary

Patients with stage-I multiple myeloma are treated with a vaccine made from their own immune cells (dendritic cells) and their own myeloma protein. Vaccinations are given on 5 occasions every 4 weeks. The aim is to induce an immune reaction against the malignant myeloma cells in order to slow down or cure the disease.

Interventions

BIOLOGICALautologous idiotype-protein pulsed dendritic cells

Vaccination with autologous idiotype-protein pulsed dendritic cells on 5 occasions every 4 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* multiple myeloma * stage I (Salmon & Durie) * no cytoreductive pre-treatment

Exclusion criteria

* myeloma stages II-III * asecretory disease

Design outcomes

Primary

Measure	Time frame
Specific T-cell proliferation/cytokine secretion	—

Secondary

Measure	Time frame
number of T cells	pre and post vaccination
monoclonal protein	pre and post vaccination
plasmacells in bone marrow	pre and post vaccination
vital signs	pre and post vaccination

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026